Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells

Cancer Letters

Volumn 316, Issue 1, 2012, Pages 77-84

  Yoon, Young Kwang ^a   Kim, Hwang Phill ^a   Song, Sang Hyun ^a   Han, Sae Won ^a,c   Oh, Do Youn ^a,c   Im, Seock Ah ^a,c   Bang, Yung Jue ^a,c   Kim, Tae You ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Cancer Hospital   (South Korea)

Author keywords

AKT; EGFR; KRAS; MEK; MIG6

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BKM 120; BORTEZOMIB; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN INDUCIBLE PROTEIN 6; SELUMETINIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL ACTIVITY; CELL MUTANT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENE CONTROL; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; KRAS GENE; MOLECULAR DYNAMICS; MONOTHERAPY; NEGATIVE FEEDBACK; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BENZIMIDAZOLES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HCT116 CELLS; HUMANS; MAP KINASE KINASE KINASES; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 84855354197     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.023     Document Type: Article

References (50)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
2. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
3. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274.
4. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., Shen D., Boca S.M., Barber T., Ptak J., Silliman N., Szabo S., Dezso Z., Ustyanksky V., Nikolskaya T., Nikolsky Y., Karchin R., Wilson P.A., Kaminker J.S., Zhang Z., Croshaw R., Willis J., Dawson D., Shipitsin M., Willson J.K., Sukumar S., Polyak K., Park B.H., Pethiyagoda C.L., Pant P.V., Ballinger D.G., Sparks A.B., Hartigan J., Smith D.R., Suh E., Papadopoulos N., Buckhaults P., Markowitz S.D., Parmigiani G., Kinzler K.W., Velculescu V.E., Vogelstein B. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
5. Shields J.M., Pruitt K., McFall A., Shaub A., Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 2000, 10:147-154.
6. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004, 4:937-947.
7. Friday B.B., Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 2008, 14:342-346.
8. Thompson N., Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol. 2005, 5:350-356.
9. McCubrey J.A., Milella M., Tafuri A., Martelli A.M., Lunghi P., Bonati A., Cervello M., Lee J.T., Steelman L.S. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr. Opin. Invest. Drugs 2008, 9:614-630.
10. Sebolt-Leopold J.S. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin. Cancer Res. 2008, 14:3651-3656.
11. Hoeflich K.P., Herter S., Tien J., Wong L., Berry L., Chan J., O'Brien C., Modrusan Z., Seshagiri S., Lackner M., Stern H., Choo E., Murray L., Friedman L.S., Belvin M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009, 69:3042-3051.
12. Joseph E.W., Pratilas C.A., Poulikakos P.I., Tadi M., Wang W., Taylor B.S., Halilovic E., Persaud Y., Xing F., Viale A., Tsai J., Chapman P.B., Bollag G., Solit D.B., Rosen N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107:14903-14908.
13. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., Morales T., Aliagas I., Liu B., Sideris S., Hoeflich K.P., Jaiswal B.S., Seshagiri S., Koeppen H., Belvin M., Friedman L.S., Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
14. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
15. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
16. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
17. Fiorini M., Alimandi M., Fiorentino L., Sala G., Segatto O. Negative regulation of receptor tyrosine kinase signals. FEBS Lett. 2001, 490:132-141.
18. Avraham R., Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 2011, 12:104-117.
19. Hackel P.O., Gishizky M., Ullrich A. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol. Chem. 2001, 382:1649-1662.
20. Yen L., Cao Z., Wu X., Ingalla E.R., Baron C., Young L.J., Gregg J.P., Cardiff R.D., Borowsky A.D., Sweeney C., Carraway K.L., 3rd Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 2006, 66:11279-11286.
21. Ryan P.E., Davies G.C., Nau M.M., Lipkowitz S. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem. Sci. 2006, 31:79-88.
22. Miller J.K., Shattuck D.L., Ingalla E.Q., Yen L., Borowsky A.D., Young L.J., Cardiff R.D., Carraway K.L., 3rd, Sweeney C. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res. 2008, 68:8286-8294.
23. Segatto O., Anastasi S., Alema S. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors. J. Cell Sci. 2011, 124:1785-1793.
24. Wick M., Burger C., Funk M., Muller R. Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation. Exp. Cell Res. 1995, 219:527-535.
25. Fiorentino L., Pertica C., Fiorini M., Talora C., Crescenzi M., Castellani L., Alema S., Benedetti P., Segatto O. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol. 2000, 20:7735-7750.
26. Fiorini M., Ballaro C., Sala G., Falcone G., Alema S., Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene 2002, 21:6530-6539.
27. Anastasi S., Fiorentino L., Fiorini M., Fraioli R., Sala G., Castellani L., Alema S., Alimandi M., Segatto O. Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 2003, 22:4221-4234.
28. Anastasi S., Sala G., Huiping C., Caprini E., Russo G., Iacovelli S., Lucini F., Ingvarsson S., Segatto O. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 2005, 24:4540-4548.
29. Xu D., Makkinje A., Kyriakis J.M. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J. Biol. Chem. 2005, 280:2924-2933.
30. Ferby I., Reschke M., Kudlacek O., Knyazev P., Pante G., Amann K., Sommergruber W., Kraut N., Ullrich A., Fassler R., Klein R. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat. Med. 2006, 12:568-573.
31. Zhang X., Pickin K.A., Bose R., Jura N., Cole P.A., Kuriyan J. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 2007, 450:741-744.
32. Zhang Y.W., Vande Woude G.F. Mig-6, signal transduction, stress response and cancer. Cell Cycle 2007, 6:507-513.
33. Zhang Y.W., Staal B., Su Y., Swiatek P., Zhao P., Cao B., Resau J., Sigler R., Bronson R., Vande Woude G.F. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 2007, 26:269-276.
34. Naruo Y., Nagashima T., Ushikoshi-Nakayama R., Saeki Y., Nakakuki T., Naka T., Tanaka H., Tsai S.F., Okada-Hatakeyama M. Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity. BMC Syst. Biol. 2011, 5:29.
35. Yoon Y.K., Kim H.P., Han S.W., Hur H.S., Oh do Y., Im S.A., Bang Y.J., Kim T.Y. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009, 8:2526-2536.
36. Ku J.L., Park J.G. Biology of SNU cell lines. Cancer Res. Treat. 2005, 37:1-19.
37. Yoon Y.K., Kim H.P., Han S.W., Oh do Y., Im S.A., Bang Y.J., Kim T.Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol. Carcinog. 2010, 49:353-362.
38. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer 1992, 50:604-610.
39. Kim H.P., Yoon Y.K., Kim J.W., Han S.W., Hur H.S., Park J., Lee J.H., Oh D.Y., Im S.A., Bang Y.J., Kim T.Y. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS ONE 2009, 4:e5933.
40. Mirzoeva O.K., Das D., Heiser L.M., Bhattacharya S., Siwak D., Gendelman R., Bayani N., Wang N.J., Neve R.M., Guan Y., Hu Z., Knight Z., Feiler H.S., Gascard P., Parvin B., Spellman P.T., Shokat K.M., Wyrobek A.J., Bissell M.J., McCormick F., Kuo W.L., Mills G.B., Gray J.W., Korn W.M. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009, 69:565-572.
41. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
42. Gopal Y.N., Deng W., Woodman S.E., Komurov K., Ram P., Smith P.D., Davies M.A. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010, 70:8736-8747.
43. Prenen H., Tejpar S., Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin. Cancer Res. 2010, 16:2921-2926.
44. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., Weber B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62:6997-7000.
45. Davies B.R., Logie A., McKay J.S., Martin P., Steele S., Jenkins R., Cockerill M., Cartlidge S., Smith P.D. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 2007, 6:2209-2219.
46. Cully M., You H., Levine A.J., Mak T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
47. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., Garcia-Echeverria C., Weissleder R., Mahmood U., Cantley L.C., Wong K.K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
48. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., Sun Y., Ouyang X., Gerald W.L., Cordon-Cardo C., Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008, 118:3051-3064.
49. Varley C.L., Armitage S., Dickson A.J. Activation of stress-activated protein kinases by hepatocyte isolation induces gene 33 expression. Biochem. Biophys. Res. Commun. 1999, 254:728-733.
50. Descot A., Hoffmann R., Shaposhnikov D., Reschke M., Ullrich A., Posern G. Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol. Cell 2009, 35:291-304.